Table 3.
Univariate and multivariate analyses of factors associated with OS.
| Characteristics | Univariate analysis | p Value | Multivariate analysis | p Value | |||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | ||||
| Age | ⩽56 versus >56 | 0.99 | 0.98–1.00 | 0.917 | |||
| Gender | Male versus female | 1.11 | 0.57–2.19 | 0.757 | |||
| ECOG | ⩽1 versus >1 | 3.16 | 1.58–6.34 | 0.001* | 2.71 | 1.33–5.53 | 0.006* |
| Lines | 1 versus ⩾2 | 1.35 | 0.82–2.23 | 0.241 | |||
| Therapy | PD-1 versus PD-1 + L | 0.82 | 0.70–0.96 | 0.015* | 0.81 | 0.68–0.96 | 0.013* |
| HBsAg | + versus − | 0.99 | 0.54–1.83 | 0.991 | |||
| EM | NO versus Yes | 0.87 | 0.53–1.48 | 0.645 | |||
| MVT | NO versus Yes | 1.67 | 1.02–2.73 | 0.042* | 1.71 | 1.03–2.84 | 0.038* |
| BCLC stage | B versus C–D | 1.59 | 0.75–3.36 | 0.224 | |||
| AFP ng/mL | <200 versus ⩾200 | 0.94 | 0.57–1.55 | 0.801 | |||
| Child–Pugh Class | A versus B | 1.44 | 0.85–2.42 | 0.174 | 1.5 | 0.87–2.56 | 0.143 |
| PD-1 inhibitors | Pembrolizumab | ||||||
| Nivolumab | 1.26 | 0.59–2.71 | 0.557 | ||||
| Others | 1.01 | 0.58–1.89 | 0.872 | ||||
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; EM, extrahepatic metastases; MVT, macrovascular tumor thrombosis; OS, overall survival.
*
p < 0.05, statistically significant.